This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hawk ET and Levin B (2005) Colorectal cancer prevention. J Clin Oncol 23: 378–391
Bresalier RS et al. (2005) A randomized trial of rofecoxib to prevent colorectal adenomas: the APPROVe trial. Gastroenterology 128: A35
Bresalier RS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102
Spektor G and Fuster V (2005) Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now? Nat Clin Pract Cardiovasc Med 2: 290–300
Chan AT et al. (2004) A prospective study of aspirin use and the risk of colorectal adenoma. Ann Intern Med 140: 157–166
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Charles S Fuchs receives research support from Pfizer, AstraZeneca, and Sanofi-Aventis.
Rights and permissions
About this article
Cite this article
Chan, A., Fuchs, C. Do cyclo-oxygenase 2 inhibitors increase the risk of cardiovascular events?. Nat Rev Clin Oncol 2, 434–435 (2005). https://doi.org/10.1038/ncponc0291
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0291